View in EDS

Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation.

Saved in:
Bibliographic Details
Title: Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation.
Authors: Frenel, J.-S.1 (AUTHOR) Jean-sebastien.frenel@ico.unicancer.fr, Lusque, A.2 (AUTHOR), Delaloge, S.3 (AUTHOR), Ferrero, J.-M.4 (AUTHOR), Bachelot, T.5 (AUTHOR), Desmoulins, I.6 (AUTHOR), Levy, C.7 (AUTHOR), Eymard, J.-C.8 (AUTHOR), Gonçalves, A.9 (AUTHOR), Patsouris, A.10 (AUTHOR), Reynier, M. A. Mouret11 (AUTHOR), Thery, M. J.-C.12 (AUTHOR), Petit, T.13 (AUTHOR), Cabel, L.14 (AUTHOR), Uwer, L.15 (AUTHOR), Debled, M.16 (AUTHOR), Chevrot, M.17 (AUTHOR), Mailliez, A.18 (AUTHOR), Jacot, W.19 (AUTHOR), de La Motte Rouge, T.20 (AUTHOR)
Source: British Journal of Cancer. Jun2023, Vol. 128 Issue 11, p2072-2080. 9p.
Database: Academic Search Ultimate
Description
ISSN:00070920
DOI:10.1038/s41416-023-02248-4